Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Pediatric Blood & Cancer|July 2, 2020
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortageRoss Mangum, M Brooke Bernhardt, W Susan Cheng, et al.
JCO Global Oncology|March 7, 2025
Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income CountryKarol Acevedo, Gabriela Soto, Mary C Shapiro, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2018
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicitiesJennifer H Foster, Patrick A Thompson, M Brooke Bernhardt, et al.
Cancer|January 24, 2023
Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexateRachel D Harris, Melanie Brooke Bernhardt, Mark C Zobeck, et al.
Pediatric Blood & Cancer|April 21, 2025
What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric MalignanciesZachary L Taylor, Tamara P Miller, Sarah G Board, et al.
Pediatric Blood & Cancer|May 3, 2018
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)Eric S Schafer, Rachel E Rau, Stacey Berg, et al.
Pediatric Blood & Cancer|October 10, 2024
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation managementJennifer A Belsky, Ashley Chavana, Ankona Banerjee, et al.
Pediatric Blood & Cancer|June 21, 2022
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortiumEric S Schafer, Karen Chao, Alexandra M Stevens, et al.
Pediatric Blood & Cancer|July 23, 2024
Toxicity profile of high-dose methotrexate in young children with central nervous system tumorsAshley N Chavana, Zachary L Taylor, Nicholas DeGroote, et al.
Pediatric Blood & Cancer|November 15, 2019
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)Eric S Schafer, Rachel E Rau, Stacey L Berg, et al.
Pageof 3